Analysis of Pharmacokinetic Data Provided in Japanese Package Inserts and Interview Forms Focusing on Urinary Excretion of Pharmacologically Active Species

• Published in: YAKUGAKU ZASSHI Vol. 126; no. 7; pp. 489 - 494
• Main Authors: HISAKA, Akihiro, SUZUKI, Hiroshi, YANAGIHARA, Yoshitsugu, KUSAMA, Makiko, OHNO, Yoshiyuki
• Format: Journal Article
• Language: English
• Published: Japan The Pharmaceutical Society of Japan 01.07.2006; Pharmaceutical Society of Japan
• Subjects: Administration, Oral; Biological Availability; drug information; Drug Information Services; Drug Labeling; Humans; interview form; Japan; package insert; Pharmaceutical Preparations - administration & dosage; Pharmaceutical Preparations - urine; pharmacokinetic data; Pharmacokinetics; Renal Insufficiency - urine; Japan
• ISSN: 0031-6903; 1347-5231; 1347-5231
• DOI: 10.1248/yakushi.126.489

In optimizing oral pharmacotherapy for patients with renal failure, information on actual urinary excretion ratio of the unchanged drug, which is obtained by dividing a urinary excretion ratio by a bioavailability after oral dose, is quite helpful. In addition, urinary excretion ratio of the active species is sometimes equally important where metabolites have a pharmacological potency. In the present study, we conducted a survey of Japanese package inserts and interview forms of drugs, which is being prescribed at the University of Tokyo Hospital, on pharmacokinetic data that enables an estimation of actual urinary excretion ratio. The total urinary excretion of a drug was documented in 70.1% of package inserts and 84.5% of interview forms, respectively. The total urinary excretion is often measured by radioactivity and thus includes its metabolites and degradation products. However, inclusion of degradation products/metabolites was described explicitly for 43.7% and 66.2%, and the absolute fraction of the unchanged drug or degradation product/metabolite was given only for 29.0% and 48.9% in package inserts and interview forms, respectively. The pharmacological activity of metabolite(s) was documented for 19.8% and 54.3%, and the oral bioavailability was described only for 5.7% and 30.6% in respective documents. For some drugs, the time period for the urine collection was too short to evaluate the urinary excretion ratio. With regard to 65 drugs (38.7%), more detailed information on urinary excretion was found in published books, but not provided in the package inserts or interview forms. It is hoped that more distinct and sufficient descriptions on the urinary excretion and bioavailability will be associated to the package inserts and the interview forms in future, for safe and efficient use of prescription drugs.